Search by ticker code:
Generic filters

Search by ticker code:
Generic filters

Search by ticker code:
Generic filters

2 great ASX growth shares I’d buy in 2022

2022 looks like a really good year to look at promising ASX growth shares.

Plenty of attractive businesses have seen their share prices drop recently like Webjet Limited (ASX: WEB), Adore Beauty Group Ltd (ASX: ABY) and Temple & Webster Group Ltd (ASX: TPW). I think that all of the ones I just mentioned look like good opportunities.

But I reckon that these two stocks have really good growth potential in 2022 and beyond:

Hearts and Minds Investments Ltd (ASX: HM1)

Hearts and Minds Investments is a very interesting listed investment company (LIC). It is a portfolio of between 25 to 35 shares of Australian and global shares based on the highest conviction picks from leading fund managers. There are no investment fees, instead that money is donated to medical research institutes.

Some of the fund managers involved includes Caledonia, Cooper, Paradice and Regal.

Over the last three years, the Hearts and Minds Investments portfolio has produced average returns of 22.9% per year, beating the global share index by 4.9% per year. There has been significant underperformance over the last 12 months, so this could be an opportune time to look at the shares.

Each business in the ASX growth share’s portfolio is picked because of the large potential that the fund manager believes that stock has.

At the current Hearts and Minds Investments share price it is at a 4% discount to the pre-tax underlying value of the portfolio – the net tangible assets (NTA). A good long-term performer at a small discount is good for me, as well as the medical backing it gives.

Volpara Health Technologies Ltd (ASX: VHT)

I think that Volara is one of the most promising ASX shares, with operations in the med tech space. It’s looking to help diagnose and provide other services relating to breast cancer and now lung cancer.

Volpara has built an impressive market share. In the US around a third of US women who have a breast scan have at least one of Volpara’s products used on their images.

Whilst the business is working hard at growing its average revenue per user (ARPU) in the US, there is plenty of geographic growth potential for Volpara into places like the EU and UK.

The ASX growth share isn’t generating a net profit yet. But for now it’s investing heavily for growth and development. Future profitability looks very good considering the gross profit margin is actually more than 91%. That allows the business to spend almost all of the new revenue on growing and improving the business like marketing, research and operational capabilities.

HY22 saw subscription revenue soar 35% to NZ$11.8 million whilst annual recurring revenue (ARR) reached NZ$29 million (up from up NZ$19.9 million a year ago).

Volpara’s share price has dropped almost 20% since 25 October 2021 despite its ARR being the highest it has been.

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report — or get it emailed to you — for FREE by CLICKING HERE NOW or the button below.

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

At the time of publishing, Jaz does not have a financial or commercial interest in any of the companies mentioned.
Skip to content